BeyondSpring Pharmaceuticals is a global clinical-stage biopharmaceutical company that was focused on the development of innovative immuno-oncology cancer therapies. Its lead asset, Plinabulin, was being developed as a direct anti-cancer agent and for the prevention of chemotherapy-induced neutropenia. The company also had a pipeline of pre-clinical immuno-oncology drug candidates. In December 2023, BeyondSpring Inc. and its subsidiaries filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware. Operations and future development are subject to the outcomes of these proceedings.
Served as the global corporate headquarters, overseeing strategic direction, investor relations, and U.S. clinical development operations before the Chapter 11 bankruptcy filing.
Located in a prominent downtown Manhattan skyscraper, 28 Liberty Street, offering access to financial and business hubs. Specific internal features are not widely publicized.
Prior to bankruptcy, likely a fast-paced, results-driven environment typical of clinical-stage biotech companies, with a focus on scientific innovation and achieving clinical milestones. Cross-cultural collaboration between U.S. and China teams was a key aspect. Current work environment is subject to restructuring.
The New York HQ provided access to U.S. capital markets, regulatory bodies (FDA), and a talent pool for clinical development and corporate functions. Its operational significance is now fundamentally altered by the bankruptcy proceedings.
Prior to its Chapter 11 filing, BeyondSpring Pharmaceuticals operated with a global footprint, primarily between the United States and China. Its U.S. operations focused on corporate strategy, financing, investor relations, and clinical development oversight for global trials. Its China operations were crucial for research and development, preclinical studies, and managing clinical trials within the Asia-Pacific region. This dual-country presence aimed to leverage talent and resources from both major pharmaceutical markets. The current extent of global operations is minimal and subject to bankruptcy proceedings.
28 Liberty Street, 39th Floor
New York
NY
USA
Address: BeyondSpring (Dalian) Pharmaceutical Co., Ltd., No. 2-1, 7th Road, Shuzigang, Ganjingzi District, Dalian, Liaoning Province, China (or similar addresses in Dalian High-Tech Industrial Zone)
To leverage local scientific talent, conduct research and development, manage clinical trials in the Asia-Pacific region, and engage with the Chinese pharmaceutical market and regulatory authorities (NMPA). Activities are likely ceased or heavily curtailed.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, BeyondSpring' leadership includes:
BeyondSpring has been backed by several prominent investors over the years, including:
The period leading up to BeyondSpring's Chapter 11 filing in December 2023 saw significant leadership changes, particularly in key financial and medical roles, amidst clinical trial setbacks and increasing financial pressures.
Discover the tools BeyondSpring uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats for BeyondSpring Pharmaceuticals likely followed standard corporate patterns such as [first_initial][last_name]@beyondspringpharma.com. Given the company's Chapter 11 status, email communication channels are likely inactive or unmonitored for most former employees.
[first_initial][last]@beyondspringpharma.com
Format
lhuang@beyondspringpharma.com
Example
10%
Success rate
FierceBiotech • December 8, 2023
BeyondSpring Pharmaceuticals and its U.S. subsidiaries filed for Chapter 11 bankruptcy protection following clinical trial disappointments for its lead candidate, Plinabulin, and subsequent financial difficulties. The filing aims to facilitate a restructuring or sale of assets....more
BioSpace • December 11, 2023
Global biopharmaceutical company BeyondSpring Inc. announced its voluntary petition for Chapter 11 bankruptcy in the U.S. The move comes after challenges with its lead drug candidate Plinabulin and aims to preserve value for stakeholders during a restructuring process....more
Nasdaq / SEC Filing • December 18, 2023
Following its Chapter 11 bankruptcy filing, BeyondSpring Pharmaceuticals' common stock (BYSI) was delisted from the Nasdaq Stock Market. Trading was suspended on December 7, 2023, and Nasdaq subsequently filed a Form 25 to formally delist the securities....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including BeyondSpring, are just a search away.